What is Ticagrelor?

Category: Prescription Drugs

Most popular types: Brilinta Brilique

false

Ticagrelor is a platelet inhibitor that is designed to reduce the number of clotting-related events within the cardiovascuar system, particularly in patients with acute coronary syndrome (such as heart attack or unstable angina).

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Heart attack (myocardial infarction) 7 1
Prevent blood clotting 6 5
Coronary artery disease 3 3
Atherosclerosis 1 0
Chest pain 1 0
Hyperlipidemia 1 0

Show all 7 reasons taken


  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 3
Mild 1
None 2

Commonly reported side effects and conditions associated with Ticagrelor

Side effect Patients
Bruising 2
Headaches 1

Dosages

Based on patients currently taking Ticagrelor

Dosage Patients
90 mg twice daily 4
60 mg twice daily 2
180 mg daily 1

Why patients stopped taking Ticagrelor

Multiple reasons could be selected

Reason Patients
Doctor's advice 3
Change in health plan coverage 1
Course of treatment ended 1
Expense 1
See all 5 patients who've stopped taking Ticagrelor

Duration

Currently taking Ticagrelor

Duration Patients
1 - 6 months 2
6 months - 1 year 2
1 - 2 years 2
2 - 5 years 1

Stopped taking Ticagrelor

Duration Patients
Less than 1 month 1
1 - 6 months 1
6 months - 1 year 1
1 - 2 years 2
Adherence
Adherence Evaluations
Always 6
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 1
A little hard to take 2
Not at all hard to take 3
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 2
Not specified 4

What people switch to and from

Patients stopped taking Ticagrelor and switched to:

Treatment Patients
Clopidogrel (Plavix) 2
Prasugrel (Effient) 1
Ramipril (Altace) 1
Last updated:
There are no evaluations for Ticagrelor.